Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert, C Schachter, J Long, G Arance, A Grob, J Mortier, L Daud, A Carlino, M McNeil, C Lotem, M
Robert, C
Schachter, J
Long, G
Arance, A
Grob, J
Mortier, L
Daud, A
Carlino, M
McNeil, C
Lotem, M
Citations
Altmetric:
Abstract
The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.
Affiliation
Description
Date
2015-06-25
Publisher
Collections
Keywords
Type
Article
Citation
Pembrolizumab versus Ipilimumab in Advanced Melanoma. 2015, 372 (26):2521-32 N. Engl J Med